msq.mosaeQ.com: A Quantum Ontology for Translational Preclinical Safety Concordance

Read full text Summarise with VIRAT
Authors: F. Hanna Campbell
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This preprint describes the proprietary framework behind msq.mosaeQ.com (Molecular Structure Quantization), a quantum ontology designed by the author to improve translational drug safety. Traditional preclinical-to-clinical concordance often fails due to two bottlenecks: the "vocabulary gap" in mapping animal findings to human adverse events, and "plasma-tissue dissociation," where systemic blood levels fail to predict localized tissue toxicity. Methodology: Every molecular entity is encoded as a triplet of angular coordinates on a unit sphere via a proprietary Non-Euclidean Molecular Partitioning (NEMP) algorithm. These coordinates are mapped into a unit quaternion on an S3 hypersphere. This allows for geodesic distance-based comparisons of molecules based on their structural "instruction set" (LogP, TPSA, and Molecular Weight) rather than nomenclature. Key Contributions: Name-Matching Resolution: Demonstrates how structural proximity on S3 can resolve name-matching failures in public databases (e.g., resolving Melflufen to its parent alkylator Melphalan). Concordance Scored against Public Databases: Systematic cross-referencing against FDA FAERS, NTP DrugMatrix, Open TG-GATEs, and NLM DailyMed. Sequestration Mapping: Incorporates a structural framework to identify potential "tissue hotspots" and lysosomal sequestration liabilities that are invisible to standard plasma-based pharmacokinetics. The platform serves as a New Approach Methodology (NAM) to provide a computational baseline for compounds where human post-market data is absent or divergent.

Fields of Study & Subjects

Computational Drug Discovery Methods Animal testing and alternatives Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN
Document type
Preprint